Access to anti-retroviral drugs, female in Tajikistan

Tajikistan: Access to anti-retroviral drugs, female was 95.0% in 2024. ◆ Volatile

Latest (2024)
95.0%
Change on year
up 8.0%
World rank
19th
of 141 countries
All-time high
95.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Tajikistan, 2000–2024

0204060801002000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 0 %2006: 1 %2007: 1 %2008: 2 %2009: 3 %2010: 5 %2011: 8 %2012: 10 %2013: 13 %2014: 21 %2015: 31 %2016: 40 %2017: 48 %2018: 56 %2019: 66 %2020: 73 %2021: 78 %2022: 83 %2023: 88 %2024: 95 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Tajikistan stood at 95.0%. That is the highest value across all 25 years on record.

The figure is up 8.0% on the previous year and up 352.4% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Tajikistan peaked at 95.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Tajikistan 19th out of 141 countries with data for 2024, putting it in the top quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Tajikistan, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Tajikistan, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 1.0%
2007 1.0% +0.0%
2008 2.0% +100.0%
2009 3.0% +50.0%
2010 5.0% +66.7%
2011 8.0% +60.0%
2012 10.0% +25.0%
2013 13.0% +30.0%
2014 21.0% +61.5%
2015 31.0% +47.6%
2016 40.0% +29.0%
2017 48.0% +20.0%
2018 56.0% +16.7%
2019 66.0% +17.9%
2020 73.0% +10.6%
2021 78.0% +6.8%
2022 83.0% +6.4%
2023 88.0% +6.0%
2024 95.0% +8.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 0.7% 0.0% 3.0% 10
2010s 29.8% 5.0% 66.0% 10
2020s 83.4% 73.0% 95.0% 5

Countries ranked near Tajikistan

  1. 19 Cameroon 95.0% compare
  2. 19 Sierra Leone 95.0% compare
  3. 22 France 93.0% compare
  4. 22 Malawi 93.0% compare
  5. 22 Morocco 93.0% compare

See the full ranking of 160 places →

More gender data for Tajikistan

All data for Tajikistan →

Frequently asked questions

What is access to anti-retroviral drugs, female in Tajikistan?
Access to anti-retroviral drugs, female in Tajikistan was 95.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Tajikistan?
The highest recorded value was 95.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Tajikistan?
The lowest recorded value was 0.0% in 2000.
How does Tajikistan rank for access to anti-retroviral drugs, female?
Tajikistan ranks 19th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Tajikistan?
Over the last ten years it is up 352.4%. The long-run trend across the full record is volatile.
Where does this Tajikistan data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Tajikistan. Statizoid, drawing on UNAIDS estimates. Retrieved 13 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/tajikistan/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/tajikistan/">Access to anti-retroviral drugs, female in Tajikistan</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.